WAYNE, PA — Teleflex (NYSE: TFX) reported new clinical data supporting two of its urology products as the company prepares to divest its Interventional Urology business later this year, a transaction that is part of a broader effort to focus on critical-care and hospital markets.
The data were presented at the 2026 American Urological Association Annual Meeting in Washington, D.C., and the European Society for Radiotherapy & Oncology Congress in Stockholm.
The studies evaluated the UroLift System for benign prostatic hyperplasia (BPH), commonly known as enlarged prostate, and the Barrigel rectal spacer used in prostate cancer radiation treatment.
A randomized controlled trial known as CLEAR compared the UroLift System directly against Rezūm, marking what Teleflex described as the first prospective, multicenter head-to-head study of the two minimally invasive BPH procedures.
According to results presented by Dr. Bilal Chughtai of Northwell Health, patients treated with UroLift achieved catheter independence more quickly following treatment.
Between days three and seven after the procedure, 3% of UroLift patients required a catheter compared with 20% of patients treated with Rezūm.
The study also found improved early patient experience among UroLift recipients, while both treatments demonstrated similar durability through 12 months.
Investigators reported that sexual function was preserved through one year among patients treated with UroLift.
“What stands out in our CLEAR RCT study is the consistency of the early patient experience advantages with the UroLift System, particularly catheter independence, rapid recovery, and preservation of sexual function,” Chughtai said.
Separate data presented at the ESTRO conference examined long-term outcomes for Barrigel, a spacer placed between the prostate and rectum to reduce radiation exposure during prostate cancer treatment.
Three-year follow-up results showed no patients treated with Barrigel experienced Grade 2 or higher gastrointestinal toxicity, compared with 10% of patients in the control group.
Researchers also reported better bowel quality-of-life outcomes among patients who achieved greater separation between the prostate and rectum during treatment.
“The three-year data further validate the clinical value of Barrigel rectal spacer, demonstrating sustained and clinically meaningful reductions in gastrointestinal toxicity,” said Dr. Martin King of Dana-Farber Brigham Cancer Center and Harvard Medical School.
The data arrive as Teleflex continues preparations to separate its Interventional Urology division, which includes the UroLift and Barrigel product lines. The company has indicated the divestiture is expected to occur during the second half of 2026.
For prospective buyers, the new studies provide additional clinical evidence supporting two of the division’s primary growth assets in markets focused on minimally invasive urological procedures and prostate cancer treatment.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.